Ignite Creation Date:
2025-12-24 @ 3:29 PM
Ignite Modification Date:
2026-01-04 @ 4:20 PM
Study NCT ID:
NCT01710592
Status:
COMPLETED
Last Update Posted:
2013-01-10
First Post:
2012-10-15
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Phase II Trial of Epirubicin, Oxaliplatin and Capecitabine (EOX) Versus Docetaxel and Oxaliplatin (ElTax) in the Treatment of Advanced Gastro-oesophageal Cancer
Sponsor:
Cancer Trials Ireland
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2007-05
Start Date Type:
None
Primary Completion Date:
2012-12
Primary Completion Date Type:
ACTUAL
Completion Date:
None
Completion Date Type:
None
First Submit Date:
2012-10-15
First Submit QC Date:
None
Study First Post Date:
2012-10-19
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2013-01-08
Last Update Post Date:
2013-01-10
Last Update Post Date Type:
ESTIMATED